Literature DB >> 24122817

Management of recurrent rectal cancer: practical insights in planning and surgical intervention.

Heather L Yeo1, Philip B Paty.   

Abstract

Over the last two decades the oncologic treatment results for primary rectal cancer have improved due to refinements in neoadjuvant chemotherapy, radiation, and surgery. Nevertheless, there is still a 10% rate of local recurrence, threatening the survival and quality of life of affected patients. Due to variability of anatomy and clinical presentation, detection, staging, and clinical management are complex. Without treatment, patients will suffer from progressive local symptoms-pain, obstruction, hemorrhage, sepsis-and rarely survive beyond five years. The overall goals of surgical treatment-complete tumor resection, preservation of function, and avoidance of complications-are identical to those of surgery for primary rectal cancer, but are unfortunately much more difficult to achieve in the setting of recurrence. Tumor resection is highly challenging, as the surgical field has generally been anatomically disrupted and irradiated, and the tumors are typically adherent or invasive into organs in the middle and low pelvis. Standard total mesorectal excision (TME) resections are rarely sufficient, and therefore techniques to achieve extended multivisceral resections are required. While aggressive resections offer the best opportunity for local control, palliation, and cure, they also carry a high risk of complications and long-term morbidity. The aim of this review is to provide an updated look at surgical resection for recurrent rectal cancer, its indications, preoperative considerations, operative technique, intraoperative radiotherapy (IORT) and long-term outcomes and sequelae.
© 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  exenteration; rectal cancer; recurrent rectal cancer

Mesh:

Year:  2013        PMID: 24122817     DOI: 10.1002/jso.23457

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  6 in total

1.  Extended lateral pelvic sidewall excision (ELSiE): an approach to optimize complete resection rates in locally advanced or recurrent anorectal cancer involving the pelvic sidewall.

Authors:  I Shaikh; W Aston; G Hellawell; D Ross; S Littler; D Burling; M Marshall; J M A Northover; A Antoniou; J T Jenkins
Journal:  Tech Coloproctol       Date:  2014-11-08       Impact factor: 3.781

2.  Impact of multimodal therapy in locally recurrent rectal cancer.

Authors:  Y N You; J M Skibber; C-Y Hu; C H Crane; P Das; E S Kopetz; C Eng; B W Feig; M A Rodriguez-Bigas; G J Chang
Journal:  Br J Surg       Date:  2016-03-02       Impact factor: 6.939

3.  Impact of age on efficacy of postoperative oxaliplatin-based chemotherapy in patients with rectal cancer after neoadjuvant chemoradiotherapy.

Authors:  Xuan-Zhang Huang; Peng Gao; Yong-Xi Song; Jing-Xu Sun; Xiao-Wan Chen; Jun-Hua Zhao; Bin Ma; Jun Wang; Zhen-Ning Wang
Journal:  Oncotarget       Date:  2016-04-12

4.  Irreversible Electroporation to Treat Malignant Tumor Recurrences Within the Pelvic Cavity: A Case Series.

Authors:  L G P H Vroomen; H J Scheffer; M C A M Melenhorst; N van Grieken; M P van den Tol; M R Meijerink
Journal:  Cardiovasc Intervent Radiol       Date:  2017-05-03       Impact factor: 2.740

5.  Radiotherapy for locally recurrent rectal cancer treated with surgery alone as the initial treatment.

Authors:  Hidekazu Tanaka; Takahiro Yamaguchi; Kae Hachiya; Sunaho Okada; Masashi Kitahara; Katsuya Matsuyama; Masayuki Matsuo
Journal:  Radiat Oncol J       Date:  2017-03-31

6.  Dose-Escalated Radiotherapy for the Treatment of Patients With Recurrent Colorectal Cancer.

Authors:  Hyung Jin Kim; Seong Taek Oh
Journal:  Ann Coloproctol       Date:  2016-04-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.